Carbidopa/Levodopa Fractional Tablet Now Available for Parkinson’s Disease

A carbidopa/levodopa tablet formulation (Dhivy) designed to facilitate dose adjustment is now available for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. It is the first and only carbidopa/levodopa tablet designed to be divided for precise dosing.

The table is supplied as a functionally scored tablet containing 25 mg of carbidopa and 100 mg of levodopa. Each tablet has three scores with each segment containing 6.25 mg of carbidopa and 25 mg of levodopa. Tablets can be broken at the score lines if a patient has difficulty swallowing it due to its size.

Dhivy is a product of Alora Pharmaceuticals. Consult product labeling for full prescribing information.

Join our email list

Get new course alerts, newsletters and more delivered directly to your inbox

By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.